Leaders in Pharmaceutical Business Intelligence (LPBI) Group

3:30PM –5:15PM, January 26, 2015 – NGS Applications: Impact of Genomics on Cancer Care @Silicon Valley 2015 Personalized Medicine World Conference, Mountain View, CA

Reporter: Aviva Lev-Ari, PhD, RN

Real Time Conference Coverage with Social Media

@Computer History Museum by Dr. Aviva Lev-Ari, PhD, RN

3:30PM – 3:45PM Mike Pellini, Foundation Medicine (Chair)

“Comprehensive” Molecular Profiling And Big Data Is Changing The Fight Against Cancer

• Actionable if based on Clinical Trials or the literature treatment of the mutation id efficacious.

CANCER IS A DISEASE OF THE GENOME

• Single-marker molecular test
• multi-gene “Hot Spot” Test
• Comprehensive Genomic Profile – sequence all genes known to implicate Cancer – all alterations to be done within one test
• Commercial adoption – 35000 patients
• Oncology & Pathology: Perform Test deliver information
• FoundationCore – Capture information in a database — who to take this information to be able to use it
• Amount of data vast: connection of Pharma, Trials, Patients
• Pathology: disrupt their relationship — they need be integrated
• FDA – Impressive actions taken are very impressive
• Payer Organization need be integrated
• FoundationnOne – information must be transpalant: Capturing every data
• Notification – when information is ready for patient care
• Liquid biopsy: diagnosis of colon cancer, gastric cancer – NEW presentation of tumors an MD never seen before
• Patient Match 35000 patient followed – within 72 hours all 28 MDs in FoundationMedicine get the genomics data, so each will see every case.

3:45PM – 4:00PM Nicholas Dracopoli, Janssen R&D

Circulating Tumor Cells: From Enumeration to Comprehensive Characterization

LIVE FROM THE PODIUM

• Apoptosis – Patients have Outcomes Targeted Therapy vs Immunotherapy
• Tumors have different Genotypes that evolve with Time and Treatment
• Hallmark of Cancer Emerge over Time
• Diagnosis & Liquid Biopsies
• Biopsy: Tissue, invasive, freq – limited
• analysis Protein, DNA
• Negative Depletion to isolate CTCs – Cancer Tumor Cells
• Fluidigm – blood cells are split into two flows cancer tumor cells normal cells
• Genotyping and Phenotyping
• Breast Cancer CTCs – Measuring Epithelial to Mesenchymal Transition (EMT)
• plasticity of cells as a result of therapy
• RNA-based Genotype
• Capture of CTCs followed by Culture and tumorigenesis in mouse Models
• Liquid Biopsy: Genetic and Genomics data combined
• CTC and cfDNA: Cancer Patients has more DNA circulation, DNA is dying,
• Progression of tumor over time: Genomics and Epithelial transition, MGH developed the technology using Fluidigm platform

4:00PM – 4:30PM   Panel, Q&A

Krishna Yeshwant Genia, Google Ventures,  

LIVE APNEL DISCUSSION – moderated by Mike Pellini, FoundationOne – In 3-5 years Genomics will become Standard of care in the Developed Nations, leading with the US.  President of the US in State of the Union address supported Precision Medicine as a driver for COst containment for HealthCare. 

Krishna Yeshwant Genia, Google Ventures: Exciting time, Science in the next 5 years Immunotherapy will become standdard of Care

Science in the next 5 years Immunotherapy will become standard of Care, IT is emerging

Stefan Roever, Roche: Structural mutation in the Genome, root core mutation, cancer sequencing, cost effective, every cancer patient need to be sequenced tumor comparison, one read to sequence. Life technologies in his career,

Nicholas Dracopoli, Janssen– Testing improves, longitudinal data collection

4:45PM – 5:00PM 

Session Chair: Frank S. Ong, Illumina (Chair) 

Dennis Slamon, UCLA

Molecular Diversity of Human Breast Cancer: Clinical and Therapeutic Implications

The Past

• The One-Size-Fits All
• Surgery
• Radiation
• The Hodgkin’s Legacy – The Golden Age
• Disease Entities – Endocrine Therapy of Breast Cancer in the 19th Century
• 1896 – 1940
• HER2 Alteration – Overexpression Oncoprotein – shortening survival
• Survival: Target validation A, B – HER2 Receptor
• Preclinical Impact of Trastuzumab on Tumor Growth: Genentech,
• Breast Cancer Subtypes
• Breast Cancer adjuvant Chemotherapy: Treatment evolution:  Drug survival 34% 6years, only surgery 26% in 12 years 50% in 6 years
• Multiple sites within one tumor – Actionable Impact only by identification of mutations, target therapy without increased tocisity

5:00PM – 5:15PM Tom Caskey, Baylor College of Medicine

Executive Care for Genetic Disease Prevention

• Young Presidents Organization – to participate
• Genetic Screening: New-born
• Prediction of disease: Genomics, familial risk
• Disease areas: Familial Disorders, CVD, neurological
• Coronary Disease: Carotid Syndrome, Obesity,hearing deficiency, eye condition: Macular degeneration, retinitis pigmentosa
• Diabetes 2 and retinopathy
• Prostate cancer pathology
• thyroid cancer
• Hairy cell leukemia
• Lipomatosis – not available in the literature as causing disease
• Myotonic Dystrophy – pre-symptomatic allele
• Metabolome
• Report goes out to the Doctors: Bioinformaticals identified RISK.

@PMWCintl 

#PMWC15

#startup #biotech #pharmanews @BiotechNews

@BloombergNews

@CancerNews

#Cancer Therapy

#science  #innovation @BloombergTV